Humacyte, Inc.
NNASDAQ:HUMACapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Laura E. Niklason
- Full Time Employees
- 184
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 2525 East North Carolina Highway 54 Durham NC United States 27713
- IPO Date
- Sep 22, 2020
- CIK
- 0001818382
- Website
- humacyte.com
- Similar Companies
- Business
- Humacyte, Inc. (Nasdaq: HUMA) develops and manufactures universally implantable, off-the-shelf, bioengineered human tissues and organs utilizing a proprietary scalable bioengineering platform that transforms human cells into acellular tissue engineered vessels (ATEVs) and advanced constructs designed to treat injury, disease, and chronic conditions with low infection rates and regenerative potential. Core products and investigational candidates include Symvess (acellular tissue engineered vessel-tyod), FDA-approved in December 2024 for extremity vascular trauma repair; ATEVs in Phase 3 for dialysis arteriovenous access (meeting co-primary endpoints in V007 trial), peripheral artery disease, coronary artery bypass grafting, and pediatric heart disease; advanced organ systems such as BioVascular Pancreas for type 1 diabetes and lung applications; and advanced tissue constructs for urinary conduits, tracheal replacement, and esophageal replacement. The company, founded in 2004 and headquartered in Durham, North Carolina, operates primarily in the United States with a global intellectual property footprint spanning the United States, Europe, Canada, and Australia; it targets vascular surgery, trauma centers, dialysis patients, military medical facilities, and regenerative medicine markets. Recent developments encompass the FDA's completion of Symvess product batch release review enabling commercial shipments, commencement of Symvess market launch and first sales in early 2025, a $46.7 million public offering to extend cash runway, cost reductions to align with commercial and pipeline priorities including a planned supplemental BLA for dialysis in H2 2026 and IND filing for CABG, and expansion of intellectual property in September 2025 with a new U.S. patent for bioengineered esophagus alongside coverage for trachea and urinary conduits to support pipeline advancement and potential corporate partnerships.
Company News
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
Head to Head Comparison: Denali Therapeutics (NASDAQ:DNLI) versus Humacyte (NASDAQ:HUMA)
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates